Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
56
-
Total 13F shares, excl. options
-
21.9M
-
Shares change
-
+1.81M
-
Total reported value, excl. options
-
$68.5M
-
Value change
-
+$7.51M
-
Put/Call ratio
-
1.49
-
Number of buys
-
35
-
Number of sells
-
-26
-
Price
-
$3.13
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q3 2020
80 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q3 2020.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 56 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21.9M shares
of 193M outstanding shares and own 11.32% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (5.98M shares), Foresite Capital Management IV, LLC (3.33M shares), MORGAN STANLEY (2.91M shares), Think Investments LP (2M shares), ADVISOR GROUP HOLDINGS, INC. (1.36M shares), BlackRock Inc. (1.05M shares), Hudson Bay Capital Management LP (710K shares), AMERIPRISE FINANCIAL INC (655K shares), PRIMECAP MANAGEMENT CO/CA/ (500K shares), and COWEN AND COMPANY, LLC (473K shares).
This table shows the top 56 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.